Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: belladonna Clear all
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Side Effects of Atropine (SEA) Study

NCT03593044
View directory record Official record
Conditions
Myopia
Interventions
0.01% concentration atropine drops
Drug
Lead sponsor
Jeffrey J. Walline, OD PhD
Other
Eligibility
21 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

NCT02872597
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Anesthetics in Rhytidoplasty - A Comparison Study

NCT02410460
View directory record Official record
Conditions
Rhytidoplasty
Interventions
clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane
Drug · Device
Lead sponsor
Mercy Facial Plastic Surgery Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 3, 2026, 6:57 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

NCT04219982
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop®
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

NCT03435003
View directory record Official record
Conditions
Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Interventions
Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia, Dexamethasone, Ondansetron, Reglan, Compazine, Sugammadex, Propofol, dexmedetomidine, Fentanyl, Sevoflurane, Desflurane
Drug · Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effects of Low Concentration Atropine on Pupil Size and Accommodation

NCT02870478
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Low Dose Atropine on Choroidal Thickness

NCT03544827
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 3, 2026, 6:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Defecation Patterns in Constipated Patients

NCT04903470
View directory record Official record
Conditions
Constipation by Outlet Obstruction
Interventions
Bisacodyl, Atropin
Drug
Lead sponsor
The California Medical Innovations Institute, Inc.
Other
Eligibility
21 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Diego, California • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 3, 2026, 6:57 PM EDT
Recruiting Phase 4 Interventional

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

NCT07434635
View directory record Official record
Conditions
Eye Disorders
Interventions
Atropine 1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 6:57 PM EDT
Active, not recruiting Phase 2 Interventional

Myopia Control: a Comparison Study Between Atropine and MiSight

NCT05815784
View directory record Official record
Conditions
Myopia
Interventions
Atropine, MiSight contact lenses
Drug · Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
5 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 6:57 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
View directory record Official record
Conditions
Motion Sickness, Space, Motion Sickness, Sea Sickness
Interventions
DPI-386 Nasal Gel, Placebo Nasal Gel
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 4 Interventional

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, ipratropium bromide / albuterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 3, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

NCT01312844
View directory record Official record
Conditions
Depression
Interventions
Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 3, 2026, 6:57 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
View directory record Official record
Conditions
Motion Sickness, Space, Motion Simulation, Parabolic Flight
Interventions
DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine)
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 3, 2026, 6:57 PM EDT
Withdrawn Not applicable Interventional

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

NCT01613820
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 3, 2026, 6:57 PM EDT
Recruiting Phase 3 Interventional

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

NCT07095894
View directory record Official record
Conditions
Myopia
Interventions
Atropine, Spectacles with HAL, Placebo Eyedrops
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Fullerton, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 3, 2026, 6:57 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial

NCT07567040
View directory record Official record
Conditions
Myopia
Interventions
Atropine Sulfate 0.05% Oph Soln, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
6 Years to 11 Years
Enrollment
664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Berkeley, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

NCT02625181
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
Procedure · Device · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebulized Bronchodilators on Heart Rate

NCT01151579
View directory record Official record
Conditions
COPD, Sepsis, Shock
Interventions
Levalbuterol, Albuterol
Drug
Lead sponsor
Fahim Khorfan, MD
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 3, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00717054
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 3, 2026, 6:57 PM EDT